2 active not recruiting, 2 completed, 2 terminated, 1 unknown. 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Highlight Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) BO-112 - Basal Cell Carcinoma | Phase 2 | Active not recruiting | Highlight Therapeutics | 50 | 2024-05-27 | 2026-09-17 |
| Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC BO-112 in combination with ablative radiotherapy (SABR) and nivolumab, Tissue Biopsies - Non-Small Cell Lung Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 30 | 2022-06-13 | 2022-07-19 |
| BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Nanoplexed Poly I:C BO-112, Pembrolizumab - Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Early Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2021-10-13 | 2023-03-24 |
| BO-112 With Pembrolizumab in Unresectable Malignant Melanoma BO-112 plus pembrolizumab, Tissue Biopsies - Melanoma | Phase 2 | Completed | Highlight Therapeutics | 42 | 2020-12-30 | 2025-11-26 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis Hepatic Biopsy, BO-112 with pembrolizumab - Colorectal Cancer, Gastric Cancer | Phase 2 | Terminated | Highlight Therapeutics | 18 | 2020-06-17 | 2024-11-29 |
| Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors Part 1: BO-112, Part 2: BO-112 - Cancer | Phase 1 | Completed | Highlight Therapeutics | 44 | 2016-06-01 | 2024-01-29 |
Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Dermatofibrosarcoma (1) · Esophageal Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Melanoma (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Sarcoma (1) · Sarcoma, Synovial (1) · Stomach Neoplasms (1)
BO-112 (6) · pembrolizumab (3) · Nivolumab (2) · Radiotherapy (2) · Radiation (1) · Radiosurgery (1) · spartalizumab (1)
Spain (5) · United States (2) · Belgium (1) · France (1) · Israel (1) · Italy (1)
Maria E Rodriguez, PhD (1) · Marisol Quintero, PhD (1) · Richard S Finn (1) · Vanesa Pons, MD, PhD (1) · Vishruth Reddy, MD, PhD (1)
PMID 31046839, PMID 35623069, PMID 40577656
2019 (1), K08CA245181 (1)